UC3

UC3 (Universal Cancer Cure) is a clinical-stage biotechnology company focused on developing novel small molecule inhibitors for the treatment of aggressive cancers, particularly glioblastoma and other solid tumors. The company's lead candidate, UC3-001, is a first-in-class inhibitor of the ubiquitin-conjugating enzyme E2 C (UBE2C), a protein frequently overexpressed in various malignancies and associated with poor prognosis. By targeting the ubiquitin-proteasome system, UC3 aims to disrupt the cell cycle and induce apoptosis in cancer cells while sparing healthy tissue. The company is currently advancing its lead program through early-phase clinical trials to evaluate safety and efficacy in patients with recurrent or refractory brain tumors. UC3's approach represents a precision medicine strategy designed to address significant unmet needs in neuro-oncology and beyond.